 CAMBRIDGE, Mass.--BUSINESS WIRE--- ALVR celltherapy--AlloVir Nasdaq: ALVR, a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2021. We believe virus-specific T-cell therapies can have a meaningful impact in treating as well as preventing multiple devastating viral infections. This approach is groundbreaking in the field of stem cell transplantation and has the potential to transform care for patients and health care providers, said Dr. Diana B 